<DOC>
	<DOCNO>NCT00267306</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability visilizumab patient severe ulcerative colitis fail respond steroid therapy . What visilizumab ? Visilizumab antibody design reduce inflammation . Antibodies proteins normally make immune system help defend body infection foreign substance . Visilizumab think selectively affect immune system decrease inflammation , , may prevent damage intestine cause ulcerative colitis . Who participate study ? The target population study adult severe ulcerative colitis resist intravenous ( IV ) steroid . This study open patient follow characteristic : - 16-70 year old - A diagnosis ulcerative colitis verify colonoscopy barium enema perform within 36 month prior study entry - Active disease despite ongoing treatment steroid How study conduct ? Eligible participant administer visilizumab one daily injection two consecutive day . All medication study-related care , except cost in-patient hospitalization , provide qualified participant cost . This include visit , examination laboratory work . How one get information ? This study currently enrol patient hospital clinic North America Europe . For information study participate , please call 1-800-772-0482 , email InfoCenter @ pdl.com visit www.IBDtrials.com .</brief_summary>
	<brief_title>Ulcerative Colitis Study : Study Visilizumab Patients With Severe Ulcerative Colitis</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>16 70 year old A diagnosis ulcerative colitis verify colonoscopy barium enema perform within 36 month prior study entry Active disease despite ongoing treatment IV steroid</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>